Procarbazine
FIG. 7. Photomicrographs magnification, X63 ; of sections of rat testes treated with hormones, procarbazine, or both. a, Untreated control rat. All tubules show active spermatogenesis with elongating or condensed spermatids. b, Testis of rat treated for 2 weeks v&h the Nal-Glu 600 ua ka * dav ; and flutamide 20 ma ka.dav ; combination treatment 9 weiks%ter last day of hormone tre%ment: Total recovery of spermatogenesis is seen; histology is identical to that in normal control animals. c, Testis of rat 9 weeks after a single dose of 250 mg kg procarbazine. In this field, none of the tubules shows recovery of spermatogenesis. d, Testis of rat 9 weeks after a single dose of 250 m&g procarbazine given 1 day after the last day of a-week hormone treatment with Nal-Glu-flutamide. Recovery of spermatogenesis is seen in all tubules in this field, progressing to the elongating or condensed spermatid stage in many, but only to the round spermatid stage in others R.
Background--Previously, we showed that tumor necrosis factor TNF ; antagonism with etanercept, a soluble TNF receptor, was well tolerated and that it suppressed circulating levels of biologically active TNF for 14 days in patients with moderate heart failure. However, the effects of sustained TNF antagonism in heart failure are not known. Methods and Results--We conducted a randomized, double-blind, placebo-controlled, multidose trial of etanercept in 47 patients with NYHA class III to IV heart failure. Patients were treated with biweekly subcutaneous injections of etanercept 5 mg m2 n 16 ; or mg m2 n 15 ; or with placebo n 16 ; for 3 months. Doses of 5 and 12 mg m2 etanercept were safe and well tolerated for 3 months. Treatment with etanercept led to a significant dose-dependent improvement in left ventricular LV ; ejection fraction and LV remodeling, and there was a trend toward an improvement in patient functional status, as determined by clinical composite score. Conclusion--Treatment with etanercept for 3 months was safe and well-tolerated in patients with advanced heart failure, and it resulted in a significant dose-dependent improvement in LV structure and function and a trend toward improvement in patient functional status. Circulation. 2001; 103: 1044-1047. ; Key Words: heart failure myocardial contraction growth substances cytokines tumor necrosis factor.
Speech betrayeth thee. Then began he to curse and to swear, that he knew not the man. And immediately the cock crew. And Peter remembered the words of Jesus which said unto him: before the cock crow, thou shalt deny me * thrice: and went out at the doors and wept bitterly.
As we sit in the semi-darkness of Pangi's hut, . "After coming here, " says his wife, "there were many things the children needed we couldn't provide them. We had no money and even if we had money, we had no place to buy them medicines, clothes, foodstuffs, so many things. You see them grown up now, but coming here hurt us. It hurt our children worse.
Replicated in the independent sample of adults with TS P .01 ; . The rate of learning correlated inversely with the severity of tic symptoms across both samples r -0.34; P .01 ; . Thus, impaired learning accompanied more severe symptoms. Measures of declarative memory functioning, in contrast, were normal in the TS groups.
Cellular immunology immunosuppression by procarbazine : sites of action of the drug and effect on adjuvant arthritis and circulating antibody responses cellular immunology , volume 3, issue 2 , february 1972 , pages 198-212 franco quagliata, julia phillips-quagliata and george floersheim abstract the effect of procarbazine hydrochloride on adjuvant arthritis and on circulating antibody responses in the rat was studied and procrit.
Make sure you tell your doctor if you have any other medical problems, especially: alcoholism angina chest pain ; or heart or blood vessel disease or heart attack or stroke recent ; — lowered blood pressure caused by procarbazine may make problems associated with some of these conditions worse chickenpox including recent exposure ; or herpes zoster shingles ; — risk of severe disease affecting other parts of the body type 2diabetes read in diabetes ; mellitus— procarbazine may change theamount see also amount ; of diabetes medicine needed epilepsy— procarbazine may change the seizures headaches severe or frequent ; — you may not realize when a severeheadache more headache ; is caused by adangerous more dangerous ; reaction to procarbazine infection— procarbazine can reduce immunity toinfection about infection ; kidney disease— effects may be increased because of slower removal of procarbazine from the body liver disease— procarbazine can cause severe liver disease to become much worse mental illness or history of ; — some cases of mental illness may be worsened overactive thyroid— increased risk of dangerous reaction to procarbazine parkinson's disease— may be worsened pheochromocytoma— blood pressure may be affected proper use of this medicine use this medicine only as directed by your doctor.
St Cuthbert High School Multi Use Games Area 221, 790 Broadway Community High School new floodlit MUGA 219, 777 Haydock High School A Multi Use Games Area 210, 234 William Beamont Community School Gymnasium upgrade and ICT suite with 15 computer workstations. Rose Bridge High School Multi Use Games Area 193, 223 St John Fisher RC High School Multi Use Games Area 191, 409 Holy Cross Primary School & Parish Primary School Playground improvements Claremont Community School Old Trafford Community School 126, 725 Church Sacred Heart Primary School Multi Use Games Area Playground Schemes in various schools 119, 500 Bispham Endowed CE Junior School - Floodlit MUGA Linnet Clough Outdoor Adventure Outdoor Adventure Activities 108, 000 Mereside Primary School multi-use games area Horwich Parish C of E School 102, 000 Longhill School Sports Hall and Fitness Suite Test Valley School - Four Court Sports Hall Pent Valley Foundation School- Four Court Sports Hall. Hailsham Community College 2, 164, 331 000 1, 500, 000 1, 465, 000 102, 932 111, Accrington Hyndburn Park Primary School Multi Use Games Area 123, 445 147, 000 and prohibit!
CNS disorders constitute one of the most significant components of healthcare spending in the developed world, contributing to an estimated 35% of the disease burden within the seven major pharma markets. However, an increased presence of generic products and lack of innovative product launches have prompted a slowdown in market growth, which pharma and biotech companies are addressing through a shift in R&D focus towards disease areas with relatively low levels of innovation, such as Alzheimer's and Parkinson's disease. Other growth initiatives include the exploration of re-formulation strategies and the continuous improvement of side-effects profiles for existing products. The CNS Market Outlook to 2012 is a new report published by Business Insights that provides a detailed epidemiological analysis of major indications within the CNS disorders market, and examines the key factors impacting their prevalence. The current opportunities and threats facing the market are assessed and the most promising potential growth areas across all indications are highlighted. The report will also profile the companies and trends that are influencing treatment sales and use detailed forecasts to analyse the competitive dynamics of leading brands within each indication. Additionally, this report measures the promotional spend on the 2005 2006 brand portfolio's of major companies against their sales performance over the same period, to provide an outlook for the future strategies that can most effectively secure commercial success. Discover the key market trends and growth drivers of the CNS market, assess the competitive dynamics of leading pharma companies and evaluate the future prospects of major products with this new report.
All documents mentioned in this press release can be found at the MRFG website at the European Medicines Authorities Windows under the heading SOP. Information on the above mentioned issues can be obtained by the presiding chair of the MRFG: Ms. Natacha GRENIER Ministry of Public Health Pharmaceutical Inspectorate Bd. Bischoffsheim 33, local 411 1000 BRUSSELS - BELGIUM Phone: + 32 2 227 Fax: + 32 2 221 e-mail: natacha.grenier afigp.fgov.be and prolixin.
Protection of procarbazine who has.
Mutagenesis procarbazine hydrochloride has been shown to be mutagenic in a variety of bacterial and mammalian test systems and propantheline.
Ii - procarbazine systemic ; procarbazine systemic ; some commonly used brand names are: in the.
BERMUDA 46, 410 Marvell Technology Group Ltd. FINLAND 37, 500 Nokia Corporation SWITZERLAND 10, 000 Serono SA - ADR ; UNITED STATES Abgenix, Inc. BEA Systems, Inc. Cisco Systems, Inc. Collateral Therapeutics, Inc. Corning Incorporated EMCORE Corporation Genentech, Inc. International Rectifier Corporation JDS Uniphase Corporation Network Appliance, Inc. Pfizer Inc. PMC-Sierra, Inc. SanDisk Corporation Silicon Storage Technology, Inc. Sun Microsystems, Inc. Texas Instruments Incorporated Transmeta Corporation Varian Medical Systems, Inc. VERITAS Software Corporation Vertex Pharmaceuticals Incorporated Total investments Short-term investments Other assets less liabilities Net assets Approved on behalf of the Trustee, AIC Limited and propylthiouracil.
Outcomes and Impact: Developed mathematical models. Industry including small and very small processors use the models to determine compliance with the stabilization cooling ; performance standards. Tech. Transfer: The results transferred to retail food industry and FSIS - served as the scientific basis to establish standards for safe cooling rate of cooked beef and FSIS compliance guidelines for cooling heat-treated products.
| The collection of the peripheral blood or bone marrow cells. The novel feature of our study was that the cells for marking and autologous transplant were collected immediately following chemotherapy and CD34 selected before transduction, whereas in the studies of Brenner, the cells were collected long after the conventional dose induction therapy and were not CD34 selected. This suggests that the percentage of cells that are in cycle in these heavily pretreated patients promoted the integration of the retrovirus in the earlier precursor cells. In addition, this work suggested that the means are at our disposal to modify sufficient percentage of cells to generate durable and significant levels of genetically modified cells. The preclinical transduction studies, summarized in Table 2, show that the transduction frequency of these cells is and protopic.
32. A 45-year-old man has otitis externa. Likely causative pathogens include all of the following except: A. B. C. fungal agents. P. aeruginosa. S. aureus. M. catarrhalis.
Lated with insulin sensitivity calculated by FSIVGTT r 0.73 ; . A fasting G: I ratio below 4.5 predicted insulin resistance with a sensitivity of 95%, a specificity of 84%, a positive predictive value of 87%, and a negative predictive value of 94%. The main limit of this parameter is that it was derived from the data of a group of obese women and, therefore, is unlikely to be a good measure of insulin resistance in nonobese PCOS patients. Baseline fasting G: I ratio was previously shown to have good correlation with NIDDM 136 ; . However, more studies on large groups are needed to validate its utility for predicting insulin resistance in PCOS patients. Simple prediction models for insulin sensitivity in women with PCOS were recently developed. Mathematical models predicting insulin sensitivity as measured by euglycemic clamp have been constructed 137 ; Fig. 2 ; . The three models were based on waist-circumference and fasting insulin, serum triglycerides, or subscapular skin fold. Of the three models, the one based on waist circumference and fasting insulin best predict insulin resistance. The mathematical models were derived from an unselected population of PCOS patients with BMIs of 17.6 37.4 kg m2, making this model applicable to both lean and obese patients. As a significant correlation has been found between insulin resistance and abnormalities in ovarian function, it has been proposed that the higher the insulin resistance in PCOS and protriptyline.
|
Purpose: To further reduce therapy-related late effects in patients with pediatric Hodgkin's disease HD ; while maintaining the high cure rates achieved with vincristine, prednisone, procarbazine, and doxorubicin OPPA ; or OPPA cyclophosphamide, vincristine, prednisone, and procarbazine COPP ; chemotherapy and involved-field radiotherapy. The risk of testicular dysfunction was addressed by substituting etoposide for procarbazine OEPA ; in the induction therapy for boys. Radiation doses and fields were further reduced. Patients and Methods: Three hundred nineteen boys and 259 girls younger than 18 years with previously untreated HD, enrolled onto the study between 1990 and 1995, were allocated to treatment group TG ; 1 early stages ; , TG2 intermediate stages ; , or TG3 advanced stages ; . All groups underwent two cycles of OEPA boys ; or OPPA girls ; for induction chemotherapy. TG2 and TG3 continued on additional two or four cycles, respectively, of COPP. Low-dose radiotherapy was given to the initially involved sites, ie, reduced involved fields. Results: Initial response to OPPA or OEPA induction was virtually identical. Eight of 578 patients experienced early progression of HD. Thirty-seven relapses.
Figure 4. Deletion analysis reveals that mse2.9 requires 81 bp of sequence on the right side for efficient and accurate processing. A ; The thick horizontal line represents micronuclear-limited sequence of heh2.2. B ; Southern blot analysis of genomic DNA purified from transformants of heh2.2 + 38R lanes 15 ; , heh2.2 + 60R lanes 69 ; and heh2.2 + 81R lanes 1013 ; clones. Whole-cell DNA was digested and probed as in Figure 2. Longer exposure for some lanes was performed to increase visualization of DNA fragments in low abundance. C ; Sequence analysis of several deletion clone transformants as in Figure 2 and provigil.
MTHADONE, ORAL, 5 MG INJECTION, TREPROSTINIL SODIUM, BORTEZOMIB, 3.5 MG BEVACIZUMAB, 100 MG TRETINOIN, TOPICAL, 5 GRAMS INJECTION, MENOTROPINS, 75 IU INJECTION, UROFOLLITROPIN, PURIF INJECTION, FOLLITROPIN ALFA, 75 INJECTION, FOLLITROPIN BETA, 75 INJECTION, CHORIONIC GONADOTROPI INJECTION, GANIRELIX ACETATE, 25 INJECTION, PEGFILGRASTIM, 6 MG CLOZAPINE, 25 MG DIDANOSINE DDI ; , 25 MG FINASTERIDE, 5 MG MINOXIDIL, 10 MG SAQUINAVIR, 200 MG ZALCITABINE DDC ; , 0.375 MG STERILE DILUTANT FOR EPOPROSTENO EXEMESTANE, 25 MG BECAPLERMIN GEL 0.01%, 0.5 GM INJECTION, LARONIDASE, 0.58 MG INJECTION, AGALSIDASE BETA, 35 M DEXTROAMPHETAMINE SULFATE, 5 MG CALCITROL, 0.25 MG INJECTION, EFALIZUMAB, 125 MG R INJECTION, RISPERIDONE, LONG ACT INJECTION, PANTOPRAZOLE SODIUM, INJECTION, ABARELIX, 100 MG INJECTION, OLANZAPINE, 2.5 MG Z INJECTION, APOMORPHINE HYDROCHLO INJECTION, AZACITIDINE, 100 MG ANASTROZOLE, ORAL, 1 MG INJECTION, BUMETANIDE, 0.5 MG CHLORAMBUCIL, ORAL, 2 MG DEXAMETHASONE, ORAL, 4 MG DOLASETRON MESYLATE, ORAL 50 MG FLUTAMIDE, ORAL, 125 MG HYDROXYUREA, ORAL, 500 MG LEVAMISOLE HCL, ORAL, 50 MG LOMUSTINE, ORAL, 10 MG MEGESTROL ACETATE, ORAL, 20 MG ONDANSETRON HCL, ORAL, 4 MG FOR PROCARBAZINE HCL, ORAL, 50 MG PROCHLORPERAZINE MALEATE, ORAL, TAMOXIFEN CITRATE, ORAL, 10 MG TESTOSTERONE PELLET, 75 MG MIFEPRISTONE, ORAL, 200 MG MISOPROSTOL, ORAL, 200 MCG DIALYSIS STRESS VITAMIN SUPPLEME PNEUMOCOCCAL CONJUGATE VACCINE, INJECTABLE POLY-L-LACTIC ACID, R.
Message boards alternative medicine close find a drug advanced search advanced search professional consumer professional consumer procarbazine oral procarbazine - oral pronunciation: pro-kar-buh-zeen ; brand name s ; : matulane review this treatment see reviews view images procarbazine oral warnings who should not take procarbazine oral and psyllium and procarbazine.
5 On 18 January 2000, OHIM notified the applicant of an amendment made by the intervener to the list of products covered by the trade mark applied for, which would now read: `Antiallergic, steroidal, ophthalmic preparations, namely eye drops, solutions, gels and ointments used for the treatment of eye infection and inflammation'. In the same letter OHIM invited the applicant to inform it whether it maintained its opposition, which it did by letter of 4 February 2000.
Somehow affect the rate of disease progression in as they do in a number of other neoplasms. More should be so significant also been found to have including lymphoma" of any acute and studies and pyrantel.
All LT cases were pathologically confirmed to be myeloid in origin AML ; by direct examination of the bone marrow in 78 patients 86% ; and the peripheral blood smear in the remaining 13 patients. Table 2 outlines the FAB classification details that reveal that the most frequent AML subtypes were M7, M0, and M2. However, all FAB subtypes except M3 were represented. Although an increase in circulating myeloblast percentage was prevalent median, 25%; range, 0%-93% ; , LT in some patients was diagnosed by bone marrow examination in the absence of circulating blasts Table 2 ; . Clinically, LT was almost always accompanied by significant anemia and thrombocytopenia, contrasted by leukocytosis Table 2 ; . LT was also heralded by sharp progression of the diseaseassociated constitutional symptoms of fatigue, night sweats, involuntary weight loss, bone pain, and progression of organomegaly.
Figure 6 Effect of PaCO2 on PTi O2. sensor Paratrend 7, Diametrix Medical, High Wycombe, U.K. ; was inserted through an adapted Camino bolt into the brain tissue on the side of injury. Invasive arterial pressure, intracranial pressure, jugular bulb venous saturation SjO2 ; and arterial bloodgases were continuously monitored. Initial readings of PTi O2 , PTi CO2 and pH were recorded at a baseline PaCO2 of 4.5 to 5.0 kPa. The PaCO2 was then decreased in a stepwise manner to 3.0 kPa. If the SjO2 decreased to less than 50%, hyperventilation was abandoned. There was no significant change in the patient's body and brain temperature, Pa O2 and cerebral perfusion pressure. PTi CO2 decreased with a reduction in PaCO2 . There was little change in brain pH. When the data are pooled as shown in fig. 6, optimal PTi O2 occurs in the PaCO2 range of 3.54.0 kPa. PTi O2 was significantly higher between 3.5 and 4.0 kPa PaCO2 compared with baseline P: 0.0001 ; . PTi O2 was optimal between a PaCO2 and 3.5 and 4.0 kPa. This range is narrower than the previously published range.3 Key words Complications, head injury. Hyperventilation. References 1. Lundberg N, Kjallquist A, Bien C. Acta Psychiatrica et Neurologica Scandinavica 1959; 34S: 564. Muizelaar JP, Marmarou A, Ward JD, Kontos HA, Choi SC, Becker DP, Gruemer H, Young HF. Journal of Neurosurgery 1991; 75: 731739. Gupta AK, Gupta S, Al-Rawi P, Kirkpatrick P. Journal of Neurosurgical Anesthesiology in press.
Nervous system toxicity- procarbazine can cause confusion, depression, and irritability.
Renovated enlarged office is nearly complete and features some of the most current practice technologies available. Excellent growth potential, as we are in a major mall located in an aggressively developing residential area of the city. Inquiries from recent graduates welcome. Please fax CV in confidence to: 780 ; 472-9835 or email: drdch compuserve . D2011.
The authors thank David Thomas for advice on the statistical analyses. Received June 30, 2004. Accepted November 3, 2004. Address all correspondence and requests for reprints to: Fiona H. Thomas, Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa Regional Cancer Centre, Ottawa, Ontario, Canada K1H 1C4. E-mail: fthomas uottawa . F.H.T. is a Canadian Institutes of Health Research CIHR ; Strategic Initiative Fellow, funded by a Strategic Training Initiative in Research in the Reproductive Health Sciences bursary. This work is part of the Program on Oocyte Health funded under the Healthy Gametes and Great Embryos Strategic Initiative of the CIHR, Institute of Human Development, Child and Youth Health, Grant number HGG62293 and procrit.
12 Nilsson CG. Comparative quantitation of menstrual blood loss with a D-norgestrel-releasing IUD and a Nova-T-Copper device. Contraception 1977; 15: 379-87. Andersson K, Rybo G. Levonorgestrel-releasing intrauterine system in the treatment of menorrhagia. Br J Obstet Gynecol 1990; 97: 690-4. Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. J Obstet Gynecol 1991; 164: 879-83. Jaeschke R, Singer J, Guyatt GH. A comparison of seven-point and visual analogue scales. Cont Clin Trials 1990; 11: 43-51. Suvisaari J, Lhteenmki P. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system. Contraception 1996; 54: 201-8. Coulter A, Peto V, Jenkinson C. Quality of life and patient satisfaction following treatment for menorrhagia. Fam Pract 1994; 11: 394-401. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing Nova T ; IUDs during five years of use. Contraception 1994; 49: 56-72.
Site map contact advanced search home news treatment & care hiv worldwide living with hiv preventing hiv organisations hiv basics about us treatment & care espaol franais portugus p other drugs aciclovir zovirax ; adefovir dipivoxil hepsera ; albendazole zentel ; alcohol alefacept amikacin amikin ; amitriptyline hydrochloride amphotericin ampicillin penbritin ; anabolic steroids aspirin atorvastatin lipitor ; atovaquone wellvone ; autologous cd8 t-cell infusion azithromycin zithromax ; bleomycin buprenorphine butrans temgesic transtec ; bupropion zyban ; cannabis capreomycin capastat ; capsaicin axsain zacin ; carbamazepine carnitine carnitor ; caspofungin cancidas ; chloroquine avloclor malarivon nivaquine ; chop ciclosporin neoral sandimmun ; cidofovir vistide ; ciprofloxacin ciproxin ciloxan ; clarithromycin clarosip klaricid klaricid xl ; clindamycin dalacin c ; clofazimine clotrimazole canesten ; cocaine codeine phosphate comp corticosteroids co-trimoxazole septrin ; cyclophosphamide endoxana ; cycloserine cytarabine dacarbazine dtic-dome ; dapsone daunorubicin diamorphine hydrochloride heroin ; diclofenac voltarol diclomax motifene ; dihydrocodeine tartrate dihydroepiandrosterone dhea ; doxorubicin hydrochloride caelyx ; echinacea ecstasy entecavir baraclude ; epoetin alfa and beta erythromycin erymax erythrocin erythroped erythroped a ; ethambutol hydrochloride etoposide etopophos vepesid ; ezetimibe ezetrol ; famciclovir famvir ; fenofibrate lipantil supralip 160 ; fluconazole diflucan ; flucytosine ancotil ; fluorouracil fluoxetine prozac ; folate folinic acid fomivirsen foscarnet sodium foscavir ; gabapentin neurontin ; gamma-hydroxybutyrate ganciclovir cymevene ; garlic gentamicin cidomycin genticin ; glutamine hormonal contraceptives human growth hormone hypericin st johns wort ; ibuprofen imatinib glivec ; imiquimod aldara ; interferon alfa interferon beta avonex rebi betaferon ; interleukin-2 proleukin ; irinotecan hydrochloride campto ; iron isoniazid itraconazole sporanox ; ketamine ketalar ; ketoconazole nizoral ; lomustine loperamide hydrochloride imodium ; mbacod megestrol acetate megace ; metformin hydrochoride glucophage glucophage sr ; methadone hydrochloride methadose ; methamphetamine methotrexate methylphenidate hydrochloride ritalin concerta xl equasym xl ; metronidazole flagyl flagyl s metrolyl ; mexiletine hydrochloride mexitil ; mitozantrone novantrone onkotrone ; mopp morphine oramorph sevredol morcap sr morphegesic sr mst continus mxl zomorph ; n-acetyl cysteine nac ; naltrexone hydrochloride nalorex ; nimodipine nimotop ; nystatin nystan nystaform tinaderm-m ; octreotide sandostatin ; ofloxacin tarivid ; omeprazole losec ; otc paclitaxel taxol ; paracetamol paromomycin pentamidine isetionate pentacarinat ; peptide t pioglitazone actos ; phenytoin epanutin ; posaconazole pravastatin sodium lipostat ; pregabalin lyrica ; primaquine procaine hydrochloride procarbazine pro-mace mopp pyrazinamide pyrimethamine daraprim ; ranitidine zantac ; reticulose retinoic acid ribavirin copegus rebetol virazole ; rifabutin mycobutin ; rifampicin rifadin rimactane ; rifapentine rituximab mabthera ; rosiglitazone avandia ; rosuvastatin crestor ; selenium sildenafil viagra ; simvastatin zocor ; streptomycin sulfadiazine tadalafil cialis ; tea tree oil thalidomide total parenteral nutrition tramadol hydrochloride trimethoprim monotrim ; trimetrexate valaciclovir valtrex ; valganciclovir valcyte ; valproic acid depakote ; vardenafil levitra ; vinblastine sulphate velbe ; vincristine sulphate oncovin ; vitamin a vitamin b1 vitamin b12 vitamin b2 vitamin b6 vitamin c vitamin d vitamin e voriconazole vfend ; zinc support our work today you are here home treatment & care treatment & care a to z drugs other drugs atovaquone wellvone ; printer-friendly version send to a friend glossary comment atovaquone wellvone ; is an anti-protozoal drug, which is approved for the treatment of mild to moderate pneumocystis pneumonia pcp ; in people who cannot take standard therapies such as co-trimoxazole septrin bactrim.
|
